The ChemoStart program is an initiative led by Leandro Sigman, together with around thirty mentors and health experts.

The pharmaceutical group Insud Pharma has announced the ninth call for its international program for startups, ChemoStart, designed to support the launch of innovative projects in health and biomedicine, as well as to promote those already in operation.

The program is open to any health-related initiative in a variety of areas: new drugs, diagnostics, artificial intelligence, personalized medicine, biotechnology, and digital health, among others. The most important aspect is that the proposed solution must be disruptive and address a significant problem in human health.

Selected projects will receive guidance from a panel of experts and mentorship for at least six months.

Insud Pharma will also act as an investor in those projects aligned with its strategic lines of activity.

The application period will be closed on November 21ˢᵗ. After that date, each proposal will be individually evaluated, and preselected candidates will be contacted to present their projects at a Pitch Day, to be held in January 2026 in Madrid. The projects will be evaluated by an external panel of experts from different fields of entrepreneurship and healthcare.

Entrepreneurs and innovative startups interested in presenting their initiatives can apply directly through this link.

This initiative, which seeks to promote innovative and disruptive solutions that improve people’s health and well-being, is led by Leandro Sigman and supported by nearly thirty mentors from various health-related disciplines.

ChemoStart is a global program by Insud Pharma that supports startups and companies developing innovative projects in healthcare and medical innovation.